---
title: "Insights Ahead: United Therapeutics's Quarterly Earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276756874.md"
description: "United Therapeutics (NASDAQ:UTHR) is set to release its quarterly earnings report on February 25, 2026, with analysts expecting an earnings per share (EPS) of $6.77. Investors are hopeful for positive guidance following the report. In the previous quarter, the company beat EPS estimates by $0.23, but shares dropped 0.39% the next day. As of February 23, shares were trading at $474.52, reflecting a 48.05% increase over the past year, indicating bullish sentiment among long-term shareholders."
datetime: "2026-02-24T15:02:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276756874.md)
  - [en](https://longbridge.com/en/news/276756874.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276756874.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276756874.md) | [繁體中文](https://longbridge.com/zh-HK/news/276756874.md)


# Insights Ahead: United Therapeutics's Quarterly Earnings

United Therapeutics (NASDAQ:UTHR) will release its quarterly earnings report on Wednesday, 2026-02-25. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate United Therapeutics to report an **earnings per share** (EPS) of $6.77.

United Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

### Earnings Track Record

During the last quarter, the company reported an EPS beat by $0.23, leading to a 0.39% drop in the share price on the subsequent day.

Here's a look at United Therapeutics's past performance and the resulting price change:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

6.93

6.87

6.53

6.31

**EPS Actual**

7.16

6.41

6.63

6.19

**Price Change %**

0.00

\-3.00

\-3.00

1.00

![eps graph](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771945365_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### United Therapeutics Share Price Analysis

Shares of United Therapeutics were trading at $474.52 as of February 23. Over the last 52-week period, shares are up 48.05%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for United Therapeutics visit their earnings calendar on our site.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [United Therapeutics Corporation (UTHR.US)](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [United Therapeutics Insider Sold Shares Worth $5,006,100, According to a Recent SEC Filing](https://longbridge.com/en/news/281244311.md)
- [Assenagon Asset Management S.A. Buys 3,824 Shares of United Therapeutics Corporation $UTHR](https://longbridge.com/en/news/280868172.md)
- [United Therapeutics Insider Sold Shares Worth $786,032, According to a Recent SEC Filing](https://longbridge.com/en/news/281244273.md)
- [United Therapeutics Director Sold Shares Worth Over $1.0M](https://longbridge.com/en/news/280686000.md)
- [These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings](https://longbridge.com/en/news/277085456.md)